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http://www.biomedcentral.com/1755-8794/6/29RESEARCH ARTICLE Open AccessPolymorphisms in nitric oxide synthase and
endothelin genes among children with
obstructive sleep apnea
Siriporn Chatsuriyawong1,2, David Gozal1, Leila Kheirandish-Gozal1, Rakesh Bhattacharjee1, Ahamed A Khalyfa1,
Yang Wang1, Wasana Sukhumsirichart2 and Abdelnaby Khalyfa1*Abstract
Background: Obstructive sleep apnea (OSA) is associated with adverse and interdependent cognitive and
cardiovascular consequences. Increasing evidence suggests that nitric oxide synthase (NOS) and endothelin family
(EDN) genes underlie mechanistic aspects of OSA-associated morbidities. We aimed to identify single nucleotide
polymorphisms (SNPs) in the NOS family (3 isoforms), and EDN family (3 isoforms) to identify potential associations
of these SNPs in children with OSA.
Methods: A pediatric community cohort (ages 5–10 years) enriched for snoring underwent overnight
polysomnographic (NPSG) and a fasting morning blood draw. The diagnostic criteria for OSA were an obstructive
apnea-hypopnea Index (AHI) >2/h total sleep time (TST), snoring during the night, and a nadir oxyhemoglobin
saturation <92%. Control children were defined as non-snoring children with AHI <2/h TST (NOSA). Endothelial
function was assessed using a modified post-occlusive hyperemic test. The time to peak reperfusion (Tmax) was
considered as the indicator for normal endothelial function (NEF; Tmax<45 sec), or ED (Tmax≥45 sec). Genomic
DNA from peripheral blood was extracted and allelic frequencies were assessed for, NOS1 (209 SNPs), NOS2
(122 SNPs), NOS3 (50 SNPs), EDN1 (43 SNPs), EDN2 (48 SNPs), EDN3 (14 SNPs), endothelin receptor A, EDNRA,
(27 SNPs), and endothelin receptor B, EDNRB (23 SNPs) using a custom SNPs array. The relative frequencies of NOS-1,-2,
and −3, and EDN-1,-2,-3,-EDNRA, and-EDNRB genotypes were evaluated in 608 subjects [128 with OSA, and 480 without
OSA (NOSA)]. Furthermore, subjects with OSA were divided into 2 subgroups: OSA with normal endothelial function
(OSA-NEF), and OSA with endothelial dysfunction (OSA-ED). Linkage disequilibrium was analyzed using Haploview
version 4.2 software.
Results: For NOSA vs. OSA groups, 15 differentially distributed SNPs for NOS1 gene, and 1 SNP for NOS3 emerged,
while 4 SNPs for EDN1 and 1 SNP for both EDN2 and EDN3 were identified. However, in the smaller sub-group for
whom endothelial function was available, none of the significant SNPs was retained due to lack of statistical power.
Conclusions: Differences in the distribution of polymorphisms among NOS and EDN gene families suggest that these
SNPs could play a contributory role in the pathophysiology and risk of OSA-induced cardiovascular morbidity. Thus,
analysis of genotype-phenotype interactions in children with OSA may assist in the formulation of categorical risk
estimates.
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Obstructive sleep apnea (OSA), is the most prevalent
form of sleep disordered breathing both in adults and
children [1-3] and has been associated with significant
neurocognitive, metabolic, and cardiovascular morbid-
ities [4-8]. OSA is characterized by episodes of total
and/or partial collapse of the upper airway alternating
with normal breathing during sleep, leading to chronic
intermittent hypoxia and hypercapnia, sleep fragmenta-
tion and increased swings in intrathoracic pressures.
This condition may affect 1– 3% of healthy school-aged
children [2]. There is accumulating evidence that OSA is
strongly linked to cardiovascular morbidity independent
of obesity [9-11]. The presence of altered endothelial
function is currently viewed as an early risk marker of
cardiovascular disease, and is a relatively common oc-
currence in both adult and pediatric patients with OSA
[12-14], and can precede the onset of hypertension [15].
However, not every child with OSA will develop ED,
suggesting that genetic factors may play a role.
Nitric oxide synthase (NOS) is encoded by three dis-
tinct genes, namely neuronal NOS (nNOS, NOS1), indu-
cible NOS (iNOS, NOS2), and endothelial NOS (eNOS,
NOS3), which are located on chromosomes 12, 17 and 7,
respectively. Studies have examined the possibility that
SNPs in these genes may influence their expression and
functional activity, and potentially alter the predispos-
ition to cardiovascular disease [16-18]. Accordingly,
single nucleotide polymorphisms (SNPs) have been iden-
tified in NOS genes, and their association with coronary
artery disease, hypertension, and diabetes has been ex-
plored [19-22]. Considering the potential role of these
enzymes in either OSA or its downstream adverse con-
sequences, it is somewhat surprising that the potential
associations between NOS polymorphisms and OSA
remain thus far unexplored.
The endothelins (EDN) are a family of endothelium-
derived peptides that possess vasoconstrictor properties,
and are important mediators of both physiological and
pathophysiologic processes [23]. The genes encoding for
EDN-1,-2 and-3 are located on chromosomes 6, 1, and
20, respectively [24]. Several studies have been identified
various SNPs on EDN genes and also in the genes encod-
ing for their cognate receptors (EDNRA and EDNRB), and
some of these gene variants have been associated with al-
tered susceptibility and prognosis of diseases such as heart
failure, dilated cardiomyopathy, diabetic retinopathy, and
atherosclerosis [25-31]. Furthermore, genetic polymor-
phisms in the endothelin-receptor-subtype-A (EDNRA)
gene have been identified as conferring increased suscepti-
bility for OSA in adults [32].
Based on aforementioned considerations, we hypothe-
sized that single nucleotide polymorphisms (SNPs) in
NOS- and EDN-related genes in children may contributeto the risk of pediatric OSA or its downstream vascular
consequences.Methods
Subjects
The study was approved by the University of Louisville
Human Research Committee, and informed consent was
obtained from the legal caretaker of each participant. Con-
secutive healthy pre-pubertal children (ages 5–10 years)
were recruited from the community, and the cohort was
enriched for the presence of habitual snoring. All children
underwent a standard polysomnographic evaluation in the
sleep laboratory at the University of Louisville Pediatric
Sleep Laboratory, after which assessment of endothelial
function (when possible) and a blood draw were per-
formed between 7:00 to 8:00AM in fasting conditions.Overnight polysomnography
A standard overnight multichannel polysomnographic
evaluation was performed in the sleep laboratory as de-
scribed previously [33]. Sleep architecture was assessed by
standard techniques [34]. The proportion of time spent in
each sleep stage was expressed as percentage of total sleep
time (%TST). Obstructive apnea was defined as the absence
of airflow with continued chest wall and abdominal move-
ment for duration of at least two breaths [33]. Hypopneas
were defined as a decrease in oronasal flow of ≥50% with
a corresponding decrease in SpO2 of ≥4% and/or arousal
[33]. The obstructive apnea/hypopnea index was defined
as the number of apneas and hypopneas per hour of TST.
Arousals were defined as recommended [35] and included
respiratory-related (occurring immediately following an
apnea, hypopnea, or snore), technician-induced, and spon-
taneous arousals. Arousals were expressed as the total
number of arousals per hour of sleep time (arousal index).
Control children required the presence of an AHI<2 in
the absence of a history of snoring as well as no snoring
detected during the sleep study. Habitually snoring
children with AHI>2/hrTST and a nadir oxyhemoglobin
saturation <92% were considered to have OSA [33].Body mass index
Children were weighed using the InBody 320 scale
(Biospace; Cerritos, CA), and height (to 0.1 cm) was mea-
sured using a stadiometer (Holtain, Crosswell, UK). The
BMI was calculated and the BMI z-score was computed
using US Centers for Disease Control and Prevention
2000 growth standards (http://www.cdc.gov/growthcharts/)
and online software (http://wwwn.cdc.gov/epiinfo/). A
BMI z-score > 1.65 (> 95th percentile) was considered as
fulfilling obesity criteria.
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All children had arterial blood pressure measured nonin-
vasively using an automated mercury sphygmomanom-
eter (Welch Allyn; Skaneateles Falls, New York) at the
brachial artery, using the appropriate cuff size on the
non-dominant arm.[36] Systolic BP and diastolic BP in-
dices were calculated by dividing the average systolic
and diastolic pressure by the respective 95th percentile
for BP using National Heart, Lung and Blood Institute
guidelines http://www.nhlbi.nih.gov/guidelines/hypertension/
child_tbl.htm), computed for age, sex, and height. Hyperten-
sion was defined when the SBPi or DBPi was > 1.
Endothelial function tests
Endothelial function was assessed upon awakening from
the sleep study in the morning, using a modified
hyperemic test after cuff-induced occlusion of the radial
and ulnar arteries as previously described [14,15,37,38].
Briefly, a laser Doppler sensor (Periflux 5000 System,
Perimed, Jarfalla, Sweden) was applied over the volar as-
pect of the hand at the 1st finger distal metacarpal sur-
face and the hand was gently immobilized. Once
cutaneous blood flow over the area became stable, the
pressure within an inflatable cuff placed at the forearm
and connected to a computer-controlled manometer
was raised to 200 mmHg for 60 sec during which blood
flow was reduced to undetectable levels. The cuff was
rapidly deflated and the laser Doppler measured hyper-
emic responses. As previously shown, the time to peak
regional blood flow after occlusion release (Tmax) is
highly reproducible and is representative of the post-
occlusion hyperemic response, an index of endothelial
function [39]. A Tmax value ≥45 sec was considered as
the criterion for abnormal endothelial function as previ-
ously described [9,10,14,15,37,38].
DNA extraction
Peripheral blood samples were collected in vacutainer
tubes containing EDTA (Becton Dickinson, Franklin
Lakes, NJ, USA). All DNA samples were extracted using
QIAmp DNA blood kit (Qiagen, Valencia, CA) accor-
ding the manufacturer’s protocol. The concentration and
quality of the DNA were determined using a ND-1000
Spectrophotometer (Nanodrop Technologies, Wilmington,
DE, USA). The precise length of genomic DNA was deter-
mined by gel electrophoresis using 1% agarose gel. All the
purified samples were stored at −80°C until further
analyses.
Custom cardiovascular gene SNP array
The IBC array was developed using SNP and linkage dis-
equilibrium information from the HapMap as well as
data from Seattle SNPs, and National Institute of Envir-
onmental Health Sciences (NIEHS) SNPs [40]. Briefly,the IBC array contains about 50,000 SNPs from genetic
diversity across approximately 2100 genes related to car-
diovascular, inflammatory, hemostasis/coagulation, and
metabolic phenotypes and pathways. Among those
genes, we selected the NOS genes which include NOS1
(209 SNPs), NOS2 (122 SNPs) and NOS3 (50 SNPs). Fur-
thermore, we selected the EDN and EDN receptor genes
family which includes EDN1 (43 SNPs), EDN2 (48
SNPs), EDN3 (14SNPs), EDNRA (27 SNPs) and EDNRB
(23 SNPs). SNPs were clustered into genotypes with the
Illumina Beadstudio software and subjected to quality-
control filters at the sample and SNP levels separately
within each cohort. Samples were excluded for individ-
ual call rates <90%, gender mismatch, and duplicate dis-
cordance. SNPs were removed for call rates <95% or
Hardy-Weinberg Equilibrium p <10−7 in controls from
each cohort (regardless of ethnicity). Due to the low-
frequency SNPs included in the design and the aim to
capture low-frequency variants of large effect across the
large dataset, we filtered only on minor allele frequency
(MAF) < 0.005.
Total RNA isolation
Fasting peripheral blood samples were drawn from chil-
dren within the first hour after awakening and collected
in PAXgene Blood RNA tubes (Becton Dickinson, UK).
Total RNA was isolated using PAXgene Blood RNA Kit
and treated with DNase I (QIAGEN, CA), according to
the manufacturer’s protocol. The RNA quantity and integ-
rity were determined using a Nanodrop Spectrophotom-
eter and Agilent 2100 Bioanalyzer Nano 6000 LabChip
assay (Agilent Technologies, Santa Clara, CA).
qPCR validation
Quantitative real-time PCR (QRT-PCR) were performed
using the ABI 7500 instrument (Applied Biosystems,
Foster City, CA). Complementary DNA was synthesized
using a High-Capacity cDNA Archive Kit (Applied
Biosystems, Foster City, CA). Five hundred nanograms
(500 ng) of total RNA from NOSA and OSA samples
were used to generate cDNA templates for RT-PCR with
primer specific for EDN1 gene. The TaqManW Master
Mix Reagent Kit (Applied Biosystems, Foster City, CA)
was in 25 μl reactions. Various negative controls were
included in the PCR reaction to ensure specific amplifi-
cation. Triplicate PCR reactions were performed in 96-
well plates for each gene in parallel with the 18S rRNA.
The steps involved in the reaction program included: the
initial step of 2 minutes at 50°C; denaturation at 95°C
for 10 min, followed by 45 thermal cycles of denatur-
ation (15 seconds at 95°C) and elongation (1 min at 60°C).
The expression values were obtained from the cycle num-
ber (Ct value) using the Biosystems analysis software. The
threshold cycle (CT) values were averaged from each
Recruited Children
n= 970 
Excluded Children  
n= 362
Included in the study 
n= 608
Normal OSA   
N=480
OSA
n= 128
NEF 
n=84
EF 
n=38
Figure 1 Schema illustrating the recruitment process in this
study. Children were matched for age, gender and ethnicity.
Children were excluded from the study, if they had any chronic
medical conditions such as known genetic syndromes, severe
asthma or allergies, or if they were on any chronic medications.
Table 1 Demographic characteristics in children with and
without OSA
Variables NOSA OSA P-value
(n=480) (n=128)
Age (years) 7.14±1.00 7.04±0.99 0.14
Gender (% male) 58.9 55.5
Ethnicity
White Caucasian % 72 63.3
African American % 28 36.7
BMI z-score 0.81±1.24 1.23±1.38 0.002
SBP (mmHg) 105.46±10.98 105.86±8.05 0.44
DBP (mmHg) 61.80±7.65 63.96±5.53 0.11
Sleep latency (min) 23.76±23.99 19.45±20.71 0.02
REM latency (min) 151.88±62.77 155.24±80.95 0.33
TST (min) 468.77±44.90 469.28±55.29 0.46
Sleep efficiency (%) 88.79±7.89 89.35±9.80 0.28
Stage 1 (% TST) 6.08±4.61 6.05±5.85 0.48
Stage 2 (% TST) 46.32±12.73 43.62±7.93 0.002
Slow wave sleep (% TST) 27.67±9.43 28.91±8.08 0.07
REM sleep (%TST) 20.68±8.35 20.13±10.87 0.30
AHI (h-1 TST) 0.63±0.49 8.28±9.27 <0.0001
Apnea index (h-1 TST) 0.44±0.96 2.53±4.76 <0.0001
Arousal index (h-1 TST) 10.06±7.25 13.37±7.82 <0.0001
Mean SaO2 (%) 97.21±4.82 96.24±2.23 0.0006
Lowest SaO2 (%) 92.66±3.85 86.02±9.10 <0.0001
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level. These Ct values were averaged and the difference
between the 18S Ct (Avg) and the gene of interest Ct
(Avg) was calculated (Ct-diff). The relative expression of
the gene of interest was analyzed using the 2-ΔΔCT method
[41]. Quantitative results are expressed as the mean ±
standard deviation (SD). Statistical significance was evalu-
ated by the Student’s t-test.
Statistical analysis
All analyses were conducted using SPSS software (version
19.0; SPPS Inc., Chicago, Ill.), and data are presented as
mean ± SD. The association analysis was assessed by using
Pearson’s chi-square test implemented in SPSS. A P-value
< 0.05 was considered statistically significant for all ana-
lyses. Odd ratio and 95% confidence interval were calcu-
lated for the minor allele of each SNP. The Haploview
version 4.2 software (hppt://www.borad.mit.edu/mpg/hap
loview) was used to analyze the linkage disequilibrium
structure, calculating D’ to define haplotype block [42]
and to estimate haplotype frequencies. Additionally, pair-
wise linkage disequilibrium (LD) among the SNPs was
examined using Lewontin’s standardized coefficient D’
and LD coefficient r2 [43], and haplotype blocks were
defined according to the method of Gabriel et al. [42] in
Haploview 4.2 with default settings. Haplotypes within
these blocks were estimated using the estimation of
maximization algorithm [44]. The associations derived
from the comparisons across OSA and NOSA were
assessed in terms of odds ratios (OR) both unadjusted
and adjusted for age, gender, ethnicity, and obesity with
the corresponding 95% confidence interval (CI).
Results
The recruitment process of children in this study is
shown in Figure 1. As indicated in Figure 1, 970 subjects
were recruited, and 362 were excluded from the study
because they had chronic medical conditions, such as
known genetic syndromes, severe asthma or allergies, or
they were receiving chronic medications. A total of 608
children were therefore included, and divided into two
groups based on their apnea-hypopnea index (AHI)
results in the sleep study: 480 children were controls
(NOSA) and 128 children fulfilled the criteria for OSA
(OSA) based on AHI. The demographic characteristics
and polysomnographic findings of children with OSA
and NOSA groups are shown in Table 1, and show
markedly similar age, gender, and ethnic distribution
indicating that the 2 groups were overall matched for
these characteristics. As would be expected based on
category attribution criteria, the AHI, apnea index and
arousal index were all significantly higher in the OSA
group (P<0.0001). Furthermore, mean SpO2 levels in
OSA were significantly lower than NOSA group (P<0.001).
Table 2 Distributions of allele and genotype frequencies of NOS SNPs in children with and without OSA
Gene SNP Allele NOSA OSA P-value OR CI 95%
NOS1 rs9658535 A/G n=477 n=128 0.04 0.26 0.07–1.06
n % n %
AA 421 88 116 91
GA 52 11 8 6
GG 4 1 4 3
Allele A 894 94 240 94
Allele G 60 6 16 6
rs7960451 C/T n=480 n=128 0.02 0.21 0.05–0.78
n % n %
CC 417 87 112 87
TC 59 12 11 9
TT 4 1 5 4
Allele C 893 93 235 92
Allele T 67 7 21 8
rs4767524 C/G n=478 n=128 0.04 0.71 0.43–1.15
n % n %
CC 160 33 52 41
GC 242 51 49 38
GG 76 16 27 21
Allele C 562 59 153 60
Allele G 394 41 103 40
rs2293050 A/G n=478 n=128 0.0002 1.59 1.04–2.43
n % n %
AA 82 17 13 10
AG 208 44 78 61
GG 188 39 37 29
Allele A 372 39 104 41
Allele G 584 61 152 59
rs10744891 G/T n=465 n=121 0.004 1.72 0.90–3.28
n % n %
GG 185 40 35 29
TG 206 44 74 61
TT 74 16 12 10
Allele G 576 62 144 60
Allele T 354 38 98 40
rs9658354 A/T n=478 n=126 0.001 1.74 1.13–2.68
n % n %
AA 80 17 13 10
AT 211 44 79 63
TT 187 39 34 27
Allele A 371 39 105 42
Allele T 585 61 147 58
rs2139733 A/T n=478 n=128 0.002 1.65 1.08–2.52
n % n %
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Table 2 Distributions of allele and genotype frequencies of NOS SNPs in children with and without OSA (Continued)
AA 77 16 13 10
AT 209 44 78 61
TT 192 40 37 29
Allele A 363 38 104 41
Allele T 593 62 152 59
rs1520810 A/T n=478 n=127 0.03 0.86 0.38–1.94
n % n %
AA 263 55 85 67
TA 189 40 34 27
TT 26 5 8 6
Allele A 715 75 204 80
Allele T 241 25 50 20
rs471871 A/T n=478 n=127 0.01 0.55 0.37–0.82
n % n %
AA 51 11 13 10
AT 212 44 38 30
TT 215 45 76 60
Allele A 314 33 64 25
Allele T 642 67 190 75
rs528558 A/G n=479 n=128 0.03 0.61 0.41–0.92
n % n %
AA 26 5 8 6
AG 191 40 35 27
GG 262 55 85 66
Allele A 243 25 51 20
Allele G 715 75 205 80
rs816296 A/C n=478 n=127 0.04 0.58 0.38–0.89
n % n %
AA 24 5 4 3
AC 174 36 33 26
CC 280 59 90 71
Allele A 222 23 41 16
Allele C 734 77 213 84
rs579604 C/T n=479 n=128 0.04 N/A N/A
n % n %
CC 310 65 96 75
TC 158 33 32 25
TT 11 2 0 0
Allele C 778 81 224 88
Allele T 180 19 32 12
rs1552227 C/T n=479 n=128 0.02 0.47 0.22–0.97
n % n %
CC 294 61 63 49
TC 163 34 53 42
TT 22 5 12 9
Chatsuriyawong et al. BMC Medical Genomics 2013, 6:29 Page 6 of 14
http://www.biomedcentral.com/1755-8794/6/29
Table 2 Distributions of allele and genotype frequencies of NOS SNPs in children with and without OSA (Continued)
Allele C 751 78 179 70
Allele T 207 22 77 30
rs17509231 C/T n=478 n=128 0.02 0.40 0.07–2.41
n % n %
CC 395 83 92 72
TC 80 17 34 26
TT 3 0 2 2
Allele C 870 91 218 85
Allele T 86 9 38 15
rs3782221 A/G n=477 n=128 0.02 0.61 0.41–0.90
n % n %
AA 36 7 4 3
AG 213 45 47 37
GG 228 48 77 60
Allele A 285 30 55 21
Allele G 669 70 201 79
NOS3 rs1800780 A/G n=470 n=126 0.05 0.71 0.47–1.09
n % n %
AA 103 22 16 13
AG 240 51 67 53
GG 127 27 43 34
Allele A 446 47 99 39
Allele G 494 53 153 61
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systemic blood pressure among the 2 groups.
From a total of 381 SNPs assayed for the 3 NOS-1,-2
and-3 genes, 15 SNPs in the NOS1 gene and 1 SNP for
NOS3 gene exhibited statistically significant differences
in their frequencies among children with OSA and their
matched controls, even after correction for multiple
comparisons (Table 2). Linkage disequilibrium (LD) ana-
lysis of the 15 SNPs in the NOS1 gene was assessed for
both OSA and NOSA subjects. In NOSA subjects, two
haplotype blocks emerged, and are outlined in black tri-
angular regions in Figure 2 (Panel A). In OSA subjects,
the haplotype showed the presence of 2 blocks as well
(Figure 2, Panel B). The haplotype of these blocks and
their frequencies in OSA and NOSA are shown in Figure 3,
Panels A and B, respectively. Taken together, the patterns
of LD and haplotype frequencies differed between OSA
and NOSA, suggesting that some of these SNPs may con-
tribute to OSA risk.
From a total of 155 SNPs for the three EDN-1,-2 and-
3 genes and their associated EDN receptors (EDNRA
and EDNRB), there were 4 SNPs in EDN1, and 1 SNP in
both of EDN2 and EDN3, in which allelic frequencies
were significantly altered in children with OSA (Table 3).
No differences emerged for EDN receptor (EDNRA, EDNRB)SNPs. The list and the summary of the significant SNPs in
both NOS and EDN genes such as location of these SNPs,
percentage of minor allele frequency (%MAF) are shown
in Additional file 1: Table S1.
Next, we divided OSA subjects into 2 subgroups based
on their individual Tmax values, when such values were
available: OSA with normal endothelial function (OSA-
NEF), and OSA with endothelial dysfunction (OSA-ED).
As shown in Figure 4, Tmax values were significantly
higher in the 6 OSA-ED subjects compared to 17 sub-
jects with OSA-NEF (P<0.002).
In addition, we quantified the mRNA expression of
the EDN1 gene in 18 matched subjects, 9 with NOSA
and 9 with OSA using qRT-PCR. As shown in Figure 5,
EDN1 was significantly increased in children with OSA
compared to NOSA (P-value 0.0005).
Discussion
In this study, we report on the allelic frequencies associ-
ations of NOS and EDN gene families in children with
and without OSA. The frequency of specific NOS1 and
EDN1 SNPs was significantly associated with the pres-
ence of OSA, while the frequencies of all other SNPs
tested for the NOS and EDN genes did not show any
Figure 2 Pairwise linkage disequilibrium (LD) structure and 15 SNPs of the NOS1 gene. Panel (A) represents children without OSA (NOSA),
and Panel (B) represents children with OSA (OSA). The plot was generated using Haploview 4.2 with D’ Color Scheme (D’=0, D’<1 and D’=1
shown by white, shades of pink and red (respectively) and pairwise r2 values shown in diamonds. The value within each diamond represents the
pair-wise LD (correlation, measured as D’) between the two SNPs defined by the top left and the top right of the diamond. Solid lines represent
SNPs that were used in the haplotype analysis, and are part of the haplotype from SNP block whereas dashed lines represent SNPs that were
used in the analysis, but were not part of the haplotype.
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dition, a subset of the children with OSA showed evi-
dence of endothelial dysfunction even though they were
asymptomatic and identified through community-based
systematic surveys, thereby confirming previous findings
in clinical cohorts on the adverse effect of OSA on endo-
thelial function. Furthermore, in a small subset of children
for whom RNA samples were available from peripheralblood monocytes, EDN1 gene expression was elevated in
children with OSA compared to controls.
Before we discuss the potential significance of our
findings, some methodological issues deserve comment,
in particular subject selection considerations and genetic
variances. First, we excluded any child with known dia-
betes, hypertension, or any other chronic disease con-
dition. This approach could therefore have artificially
Figure 3 Haplotype frequencies in children with and without OSA. Panel (A) represents haplotype for children without OSA (NOSA), and
Panel (B) represents haplotype for children with OSA (OSA).
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NOS of EDN allelic variant with OSA. Second, we
narrowed the age range of the current cohort such as to
minimize as much as possible any confounding factors
that might be operational across a wide age range in
OSA. Thirdly, closely matched control children are in-
cluded which should minimize the effect of modifying
factors that could be involved in the process of subject
selection. In addition, the use of the laser Doppler tech-
nique for assessment of vascular responses followingcuff-induced arterial occlusion not only permits repro-
ducible determination of the kinetics of post-ischemic
reperfusion, but also serves as an accurate reporter of ni-
tric oxide-mediated physiological recruitment of the mi-
crovasculature [37,45]. In this context, we also excluded
children with a variety of diagnoses that can be associ-
ated with endothelial dysfunction [46]. The two import-
ant limitations of this study include the relatively small
size of the cohort of children studied which could ham-
per statistical power, and the absence of endothelin
Table 3 Distributions of allele and genotype frequencies of EDN SNPs in children with and without OSA
Gene SNP Allele NOSA OSA P-value OR CI 95%
EDN1 rs1014505 n=478 n=127 <0.001 1.28 0.85-1.92
C/G n % n %
CC 62 13 36 29
CG 215 45 45 35
GG 201 42 46 36
Allele C 339 35 117 46
Allele G 617 65 137 54
rs2070698 C/T n=480 n=128 0.04 1.73 1.07-2.79
n % n %
CC 102 21 37 29
CT 236 49 66 52
TT 142 30 25 19
Allele C 440 46 140 55
Allele T 520 54 116 45
rs2248580 n=478 n=128 0.02 1.07 0.72-1.59
A/C n % n %
AA 60 12 28 22
AC 208 44 46 36
CC 210 44 54 42
Allele A 328 34 102 40
Allele C 628 66 154 60
rs2070699 G/T n=479 n=128 0.002 0.42 0.25-0.69
n % n %
GG 213 45 55 43
TG 216 45 45 35
TT 50 10 28 22
Allele G 642 67 155 61
Allele T 316 33 101 39
EDN2 rs11210273 C/T n=478 n=128 0.02 NA NA
n % n %
CC 411 86 105 82
TC 67 14 21 16
TT 0 0 2 2
Allele C 889 93 231 90
Allele T 67 7 25 10
EDN3 rs6064764 C/T n=479 n=127 0.02 0.90 0.60-1.34
n % n %
CC 27 6 15 12
CT 174 36 35 27
TT 278 58 77 61
Allele C 228 24 65 26
Allele T 730 76 189 74
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Figure 4 Individual Tmax values in children with OSA and
normal endothelial function (OSA-NEF), and children with OSA
with endothelial dysfunction (OSA-ED).
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http://www.biomedcentral.com/1755-8794/6/29plasma level measurements in blood cells for the genes
of interest. Although highly desirable, the latter were not
possible due to limitations in the amount of blood
samples. However, inclusion of the present preliminary
findings on endothelial function are intent on further il-
lustrating future directions that will need to encompass
specific gene variants to not only the presence or absence
of a disorder, i.e., OSA, but also to the presence or absence
of a consequence of the disorder, i.e., endothelial dysfunction.1.9
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Figure 5 qRT-PCR analysis for EDN1 gene expression in
children with OSA and controls (NOSA). Data are presented as
relative mRNA expression levels normalized to 18s, and individual
values and boxplots are shown (OSA vs. NOSA: P-value <0.0005).We and others have previously shown significant associa-
tions between specific gene candidate variances and OSA-
associated phenotypes, and this study adds incremental
information to potentially significant contributions of EDN
and NOS gene polymorphisms to this issue [8,47-51].
However, the overall modulatory effects of these polymor-
phisms to the clinical phenotype of pediatric OSA will
have to await more extensive studies involving much larger
cohorts. Accordingly, we opted not to implement add-
itional valuable analytical methodologies to derive what we
perceive as somewhat premature inferential conclusions
from such methods [52,53].
OSA is a multi-factorial and highly prevalent disorder
in which both genetic and environmental factors may be
involved [54,55]. The role of specific genes that influence
the development of OSA is unclear. A precise genetic
foundation of OSA has been thus far difficult to identify,
because it is still unknown whether some of the putative
candidate genes for OSA are directly causal to the ex-
pression of the disorder or whether their role in OSA is
mediated through other intermediate genes. Similarly,
the phenotypic expression of OSA and its consequences
is most likely determined by multiple genetic and environ-
mental factors and their interactions. Some of the factors
assumed to operate as intrinsic genetic determinants of
susceptibility [56-58] have been shown to include inflam-
matory pathways, lipid membrane transport, and growth
factors [58]. Additional external factors that have yet to be
corroborated in clinical pediatric cohorts include lifestyle
components, such as physical activity, and dietary habits.
Previous studies have reported that several single nucleo-
tide polymorphisms might be involved in the pathogenesis
of OSA both in adult and children, such as serotonin
transporter (5-HTT) [59], TNF-α [49,60], fatty acid bind-
ing protein 4 [48,61], macrophage migration inhibitory
factor [47], NADPH oxidase p22 sub-unit [8,50], and
angiotensin I converting enzyme (ACE) [62,63].
In this study, we used 536 SNPs from different genes
and pathways to study the association of their allelic fre-
quencies in children with OSA. Here, we show in a total
of 209 SNPs assayed with NOS1 gene, we identified 15
significantly SNPs those allelic frequencies were associ-
ated in children with OSA. To the best of our know-
ledge, no studies were conducted on genetic variance of
NOS genes in children with OSA. However, several
studies have been reported in human using NOS SNPs.
For example, several polymorphisms located in NOS1,
NOS2, and NOS3 genes have been identified; some of
these polymorphic sites could be responsible for varia-
tions in the genetic control of plasma NOS levels, which
would be a useful tool for studying the relationship be-
tween NOS and diseases including asthma [64,65], de-
pressive disorder [66], Parkinson's disease [67], diabetic
nephropathy [68], and stroke [69].
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endothelin receptors (EDNR) that are activated by endothe-
lin (EDN) signaling peptides. Specific interactions between
the three different endothelin-subtypes (EDN-1, -2, -3)
and the two human endothelin receptors (EDNRA,
EDNRB) are known [70]. Endothelin-1 (EDN 1), the most
potent vasoconstrictor of the human organism, uses
mainly the EDNRA as a signal transduction pathway. Our
results show different allelic frequencies of EDN polymor-
phisms between OSA subjects and controls. For example,
of 155 SNPs for the three EDN-1,-2 and-3 genes and
their associated EDN receptors (EDNRA and EDNRB),
there were 4 SNPs in EDN1, and 1 SNP in both of
EDN2 and EDN3, in which allelic frequencies were sig-
nificantly altered in children with OSA. We are only
aware of a single published report on genetic polymor-
phisms in endothelin-receptor-subtype-a-gene as a sus-
ceptibility factor for adult OSA [32]. These investigators
identified 4 candidate SNPs out of 100 in ENDRA in pa-
tients with OSA, but did not ascertain the significance
of their findings by haplotype analysis. Endothelin-1
(EDN1) is an intercellular signaling molecule expressed
in many different organ systems and tissues. Although
EDN1 is best known as a potent vasoconstrictor, EDN1
also plays important roles in the kidney, nervous system,
and in the heart [71]. Furthermore, genetic polymorphisms
in the EDN1 promoter region have been linked to an in-
creased incidence of left ventricular hypertrophy [72], and
asthma [73], a known consequence of OSA in children
[74]. The increased expression of EDN1 among children
with OSA in the present study would further suggest that
genotype-phenotype interactions may indeed be present
in pediatric OSA and its cardiovascular morbidities. In-
deed, several lines of evidence derived from both clinical
studies and animal models have shown that increases in
circulating EDN1 in OSA [75-77].
Conclusion
In conclusion, our results suggest that the NOS1 and
EDN1 genes may confer an increased risk for the pres-
ence of OSA or downstream morbidity. The susceptibil-
ity to OSA is a multifactorial process and may result
from genetic variants in many genes on different chro-
mosomes. Also, genetic epidemiological studies of bio-
logical phenotypes involved in the same pathway can
provide relevant information, and can contribute to un-
ravel the mechanisms underlying complex diseases such
as OSA. More specifically, the changes in EDN1 gene
expression particularly when combined with differences
in the distribution of EDN1 polymorphisms, suggest
these specific SNPs influence the genetic predisposition
to OSA. Thus, analysis of the currently identified EDN1
polymorphism may be useful in the assessment of risk
for OSA in a high risk population, such as those childrenwho manifest snoring or have enlarged tonsils and aden-
oids. Further studies should be carried out to confirm the
association reported herein in expanded pediatric cohorts,
and tentatively include protein and gene expression levels
to enable deciphering the importance and functionality of
these genetic factors.
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